Xarelto
E49852
Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
All labels observed (3)
| Label | Occurrences |
|---|---|
| Xarelto canonical | 1 |
| betrixaban | 1 |
| rivaroxaban | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T391438 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Xarelto Context triple: [Johnson & Johnson, notableProduct, Xarelto]
-
A.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Xarelto Target entity description: Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
-
A.
Activase
Activase is a brand-name form of the clot-dissolving drug alteplase, widely used as a thrombolytic treatment for acute ischemic stroke and certain types of heart attack and pulmonary embolism.
-
B.
Avastin
Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
-
C.
Lucentis
Lucentis is a prescription anti-VEGF biologic drug used to treat several serious eye diseases, including wet age-related macular degeneration and diabetic macular edema, by inhibiting abnormal blood vessel growth in the retina.
-
D.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
-
E.
Vumerity
Vumerity is an oral prescription medication used to treat relapsing forms of multiple sclerosis in adults.
- F. None of above. chosen
Statements (57)
| Predicate | Object |
|---|---|
| instanceOf |
anticoagulant
ⓘ
direct oral anticoagulant ⓘ factor Xa inhibitor ⓘ pharmaceutical drug ⓘ |
| hasActiveIngredient | rivaroxaban ⓘ |
| hasAntidote | andexanet alfa ⓘ |
| hasATCCode | B01AF01 ⓘ |
| hasBioavailability | high oral bioavailability at lower doses ⓘ |
| hasBlackBoxWarning |
increased risk of thrombotic events after premature discontinuation
ⓘ
risk of spinal or epidural hematoma with neuraxial anesthesia or spinal puncture ⓘ |
| hasCommonAdverseEffect |
anemia
ⓘ
bleeding ⓘ dizziness ⓘ nausea ⓘ |
| hasContraindication |
active pathological bleeding
ⓘ
severe hypersensitivity to rivaroxaban ⓘ significant hepatic disease associated with coagulopathy ⓘ |
| hasDosingFrequency |
once daily for many indications
ⓘ
twice daily for some initial treatment regimens ⓘ |
| hasDrugClass |
antithrombotic agent
ⓘ
blood thinner ⓘ |
| hasGenericName | rivaroxaban ⓘ |
| hasHalfLife |
approximately 11 to 13 hours in elderly subjects
ⓘ
approximately 5 to 9 hours in healthy young subjects ⓘ |
| hasIndication |
prevention of stroke in nonvalvular atrial fibrillation
ⓘ
prophylaxis of venous thromboembolism after hip replacement surgery ⓘ prophylaxis of venous thromboembolism after knee replacement surgery ⓘ reduction in the risk of recurrence of DVT and PE ⓘ reduction of risk of major cardiovascular events in patients with chronic coronary artery disease ⓘ reduction of risk of major cardiovascular events in patients with peripheral artery disease ⓘ thromboprophylaxis in acutely ill medical patients at risk for thromboembolic complications ⓘ treatment of deep vein thrombosis ⓘ treatment of pulmonary embolism ⓘ treatment of venous thromboembolism in pediatric patients ⓘ |
| hasInitialFDAApprovalYear | 2011 ⓘ |
| hasMechanismOfAction |
decreases thrombin generation
ⓘ
reduces fibrin clot formation ⓘ selective inhibition of factor Xa ⓘ |
| hasPregnancyCategory | may cause fetal risk; use only if potential benefit justifies potential risk ⓘ |
| hasProteinBinding | high plasma protein binding ⓘ |
| hasSeriousAdverseEffect |
gastrointestinal bleeding
ⓘ
intracranial hemorrhage ⓘ major bleeding ⓘ |
| isComparedWith |
apixaban
ⓘ
dabigatran ⓘ warfarin ⓘ |
| isCoPromotedBy | Janssen Pharmaceuticals ⓘ |
| isDosageForm |
film-coated tablet
ⓘ
oral suspension ⓘ |
| isManufacturedBy | Bayer ⓘ |
| isMetabolizedBy |
CYP2J2
ⓘ
CYP3A4 ⓘ |
| isRouteOfAdministration | oral ⓘ |
| isSubstrateOf |
BCRP
ⓘ
P-glycoprotein ⓘ |
| isTakenWithFood | recommended for 15 mg and 20 mg doses ⓘ |
| wasApprovedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Xarelto Description of subject: Xarelto is a widely used prescription anticoagulant (blood thinner) that helps prevent and treat blood clots and reduce the risk of stroke in certain patients.
Referenced by (3)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
rivaroxaban
this entity surface form:
betrixaban